RPTX - Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 42 nd Annual Goldman Sachs Virtual Global Healthcare Conference on Wednesday, June 9 at 3:50 p.m. Eastern Time.
A live webcast of the fireside chat can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events . A replay of the webcast will be archived on the Company’s website for 30 days.
About Repare Therapeutics Inc.
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Pol? inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com .
SNIPRx ® is a registered trademark of Repare Therapeutics Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005095/en/
Repare:
Steve Forte
Chief Financial Officer
Repare Therapeutics Inc.
info@reparerx.com
Investors:
Kimberly Minarovich
Argot Partners
repare@argotpartners.com
Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902